Multiple Sclerosis Drug Market size was over USD 25.07 billion in 2024 and is expected to exceed USD 42.07 billion by the end of 2037, growing at over 4.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of multiple sclerosis drug is evaluated at USD 25.89 billion.
The market growth is primarily driven by the rising number of new drug candidates for multiple sclerosis being developed and pre-clinical trials are ongoing. Worldwide, nearly 3 million people are living with multiple sclerosis. Therefore, an increase in the number of sclerosis patients is expected to result in a rise in the need for medications and medical care.
The efficacy of the medicines and surging development in the treatment of multiple sclerosis are expected to boost market growth. In June 2021, Bristol Myer Squibb released the progressive result of the early Zepsosia treatment, nearly, 80% of patients with high thalamic volume benefitted from the drug. Furthermore, proactive government efforts for multiple sclerosis patients are expected to propel the growth of the global multiple sclerosis drug market. In India, the government proposed to add multiple sclerosis in the Ayushman Bharat Scheme, a Nation Health Protection Mission, this initiative is to reduce the cost of treatment in the country. Moreover, in China as well, the government added multiple sclerosis to the list of rare diseases to improve the treatment outcomes of the patient.
Growth Drivers
Challenges
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.2% |
|
Base Year Market Size (2024) |
USD 25.07 billion |
|
Forecast Year Market Size (2037) |
USD 42.07 billion |
|
Regional Scope |
|
Medication Type (Oral, Injection)
The multiple sclerosis drug market is segmented and analyzed for demand and supply by medication type into oral and injection. The oral segment is expected to hold the largest market size by the end of 2037, owing to its better efficacy and favorable safety profile against other available treatments. Most oral MS therapies currently on the market have been granted marketing approvals by regulatory agencies. For instance, Cipla Inc. received approval from the United States Food and Drug Administration for Tecfidera (dimethyl fumarate DR capsules), an oral drug to treat the relapsing forms of multiple sclerosis.
Our in-depth analysis of the global market includes the following segments:
|
By Drug |
|
|
By Type |
|
|
By Medication Type |
|
|
By Treatment |
|
|
By End User |
|
The North America multiple sclerosis drug market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. A few variables that are anticipated to drive the expansion of the market in North America include an increase in the global burden of multiple sclerosis among the population and a higher probability of women getting multiple sclerosis. In the United States, every week, around 200 new cases are added to the list of multiple sclerosis patients. Moreover, in 2019, nearly 400,000 people were affected by it. In North America, there are around 140 cases per 100,000 population and out of them, about 70% of patients are women, further, in the past 30 years, the ratio of women to men has jumped from 2:1 to 3:1. Furthermore, the development in the healthcare sector in North America is to elevate the growth of the market in the region. At the end of 2019, the total expenditure on health facilities in the U.S. was worth nearly 18% of the U.S. gross domestic product (GDP), and it is expected to total USD 6 trillion annually by 2028.
Biogen collaborated with Eisai Co., Ltd., for the co-promotion of multiple sclerosis treatments including Tecfidera, Tysabri, and Avonex in Japan.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?